Davis R M Inc. Sells 1,380 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Davis R M Inc. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 129,695 shares of the medical research company’s stock after selling 1,380 shares during the period. Thermo Fisher Scientific accounts for about 1.3% of Davis R M Inc.’s investment portfolio, making the stock its 23rd biggest holding. Davis R M Inc.’s holdings in Thermo Fisher Scientific were worth $64,536,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bernard Wealth Management Corp. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $25,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth approximately $30,000. IMA Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $35,000. Navigoe LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the first quarter valued at $37,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.1%

Shares of TMO opened at $477.01 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88. The company has a 50 day simple moving average of $418.15 and a two-hundred day simple moving average of $468.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market cap of $180.07 billion, a P/E ratio of 27.59, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.37 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.36%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TMO shares. Royal Bank Of Canada decreased their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. HSBC restated a “hold” rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 23rd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Finally, Stifel Nicolaus cut their target price on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. Six equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.